Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: J Hepatol. 2022 Feb 12;77(1):55–62. doi: 10.1016/j.jhep.2022.01.027

Fig. 4. Cost-effectiveness acceptability curves.

Fig. 4.

Cost-effectiveness acceptability curves showing the probability of cost-effectiveness for each surveillance strategy by different durations of hepatocellular carcinoma surveillance as defined by the stopping age in patients with (A) compensated cirrhosis and (B) advanced fibrosis. QALY, quality-adjusted life year.